Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDMA Co-administration with LSD in Healthy Subjects
NCT04516902Phase 1Completed
- Sponsor
- University Hospital Basel
- Start
- Jan 2021
- Primary completion
- Aug 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Lysergide and midomafetamine in major depressive disorder (MDD), anxiety disorder and Substance Use Disorder (SUD), sponsored by University Hospital Basel. Started Jan 2021; status: completed.
02
Drugs
Lysergidemidomafetamine
03
Conditions
major depressive disorder (MDD)anxiety disorderSubstance Use Disorder (SUD)
Beyond the preview
Go deeper on NCT04516902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04516902.